The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) Study

被引:51
作者
Durovni, Betina [2 ,3 ]
Cavalcante, Solange C. [2 ,4 ]
Saraceni, Valeria [2 ]
Vellozo, Vitoria [2 ]
Israel, Giselle [2 ]
King, Bonnie S. [5 ]
Cohn, Silvia [1 ]
Efron, Anne [5 ]
Pacheco, Antonio G. [4 ]
Moulton, Lawrence H. [5 ]
Chaisson, Richard E. [1 ,5 ,6 ]
Golub, Jonathan E. [1 ,6 ]
机构
[1] Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD 21231 USA
[2] Municipal Hlth Secretariat, Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil
[4] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[6] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
adherence; HIV; implementation; isoniazid preventive therapy; tuberculosis; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED PATIENTS; DE-JANEIRO; TUBERCULOSIS; BRAZIL; TRIAL; RISK; IMPACT;
D O I
10.1097/01.aids.0000391022.95412.a6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The TB/HIV in Rio (THRio) study was launched in September 2005 to assess the impact of integrated tuberculosis (TB) and HIV treatment strategies in 29 HIV clinics in Rio de Janeiro, Brazil. Design: THRio is a cluster-randomized trial (CRT) to determine whether routine screening for and treatment of latent TB in HIV clinic patients with access to anti-retroviral therapy will reduce TB incidence at the clinic level. THRio is part of the Consortium to Respond Effectively to AIDS/TB Epidemic that is implementing research studies to assess the impact of bold, new public health paradigms for controlling the AIDS/TB epidemic. Methods: Twenty-nine public primary HIV clinics were randomly assigned a date to begin implementing TB screening procedures and provision of isoniazid preventive therapy (IPT) for TB/HIVcoinfected patients. Final analysis of the CRT is expected in 2011. Results: Starting at date of tuberculin skin test (TST)/IPT implementation at each clinic through August 2010, 1670 HIV-infected patients initiated IPT, of which 215 are still receiving treatment. Of the remaining 1455 patients, 1230 (85%) completed therapy and only 20 (1.2%) patients initiating IPT reported adverse reactions leading to discontinuation of therapy. IPT completion was higher among HIV-infected patients receiving HAART (87%) than those not yet receiving HAART (79%, P < 0.01). Times to TST and IPT have markedly decreased postintervention, but remain considerably long. The richness of the THRio database has resulted in several analyses of this expansive cohort of HIV-infected patients that are reviewed here. Conclusions: The national implementation of TST and IPT for HIV-positive patients in Brazil has been invigorated partly due to THRio's baseline results. Expanded use of IPT in HIV patients in Rio de Janeiro is achievable with high adherence and low adverse events, although this effort requires a package of activities including training, advocacy and reorganization of services. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:S49 / S56
页数:8
相关论文
共 22 条
[1]   Treatment of latent tuberculosis infection in HIV infected persons [J].
Akolo, Christopher ;
Adetifa, Ifedayo ;
Shepperd, Sasha ;
Volmink, Jimmy .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01)
[2]  
[Anonymous], 2010, GUID INT TUB CAS FIN
[3]   Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study [J].
Badri, M ;
Wilson, D ;
Wood, R .
LANCET, 2002, 359 (9323) :2059-2064
[4]  
CASTELO A, 2004, J BRAS PNEUMOL S2, V30, pS62
[5]   The growing burden of tuberculosis - Global trends and interactions with the HIV epidemic [J].
Corbett, EL ;
Watt, CJ ;
Walker, N ;
Maher, D ;
Williams, BG ;
Raviglione, MC ;
Dye, C .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (09) :1009-1021
[6]   Chemoprophylaxis for tuberculosis and survival of HIV infected patients in Brazil [J].
de Pinho, AMF ;
Santoro-Lopes, G ;
Harrison, LH ;
Schechter, M .
AIDS, 2001, 15 (16) :2129-2135
[7]   Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection [J].
Girardi, E ;
Antonucci, G ;
Vanacore, P ;
Libanore, M ;
Errante, I ;
Matteelli, A ;
Ippolito, G .
AIDS, 2000, 14 (13) :1985-1991
[8]   The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil [J].
Golub, Jonathan E. ;
Saraceni, Valeria ;
Cavalcante, Solange C. ;
Pacheco, Antonio G. ;
Moulton, Lawrence H. ;
King, Bonnie S. ;
Efron, Anne ;
Moore, Richard D. ;
Chaisson, Richard E. ;
Durovni, Betina .
AIDS, 2007, 21 (11) :1441-1448
[9]   A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis [J].
Gordin, FM ;
Matts, JP ;
Miller, C ;
Brown, LS ;
Hafner, R ;
John, SL ;
Klein, M ;
Vaughn, A ;
Besch, CL ;
Perez, G ;
Szabo, S ;
ElSadr, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :315-320
[10]   Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection [J].
Halsey, NA ;
Coberly, JS ;
Desormeaux, J ;
Losikoff, P ;
Atkinson, J ;
Moulton, LH ;
Contave, M ;
Johnson, M ;
Davis, H ;
Geiter, L ;
Johnson, E ;
Huebner, R ;
Boulos, R ;
Chaisson, RE .
LANCET, 1998, 351 (9105) :786-792